Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04452526 · ClinicalTrials.gov registry record · NA

I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination

A NA study of Cervical Carcinoma and Human Papillomavirus-Related Malignant Neoplasm, sponsored by Ohio State University Comprehensive Cancer Center.

Active
Registry status
NA
Development phase
372
Enrollment target
4
Study locations

NCT04452526: Active NA study of Cervical Carcinoma and Human Papillomavirus-Related Malignant Neoplasm, sponsored by Ohio State University Comprehensive Cancer Center.

NCT04452526 is a NA study of Cervical Carcinoma and Human Papillomavirus-Related Malignant Neoplasm that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 372 participants, below the 521-participant average among 25 other Cervical Carcinoma trials with a reported enrollment target (29% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04452526, a NA study of Cervical Carcinoma and Human Papillomavirus-Related Malignant Neoplasm, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
372 participants
Enrollment target
4
Study locations

Study Summary

This trial studies how well a multi-level health system-based intervention works in improving human papillomavirus (HPV) vaccine initiation and completion among children in health systems in four Appalachian states. Utilizing educational and promotional materials and electronic health record reminders, may improve the uptake of the HPV vaccine in children and young adults, ultimately preventing the development of cervical cancer.

Primary Outcome

The effectiveness of the intervention will be assessed by comparing early vs delayed intervention clinics at the end of the first implementation phase adjusting for baseline rates and pre- versus (vs) post implementation rates in the delayed implementation clinics.

Interventions

  • OTHER Questionnaire Administration
  • OTHER Best Practice
  • OTHER Educational Intervention
  • OTHER Reminder

Study Locations (4)

Kentucky

  • University of Kentucky/Markey Cancer Center - Lexington

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Virginia

  • University of Virginia - Charlottesville

West Virginia

  • West Virginia University - Morgantown

Trial Details

FieldValue
Enrollment Target 372 participants
Start Date 2020-10-21
Est. Completion 2025-09
Phase NA

What the registry record for NCT04452526 still lists

NCT04452526 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 521-participant average among 25 other Cervical Carcinoma trials with a reported enrollment target (29% lower).

The record links to 2 conditions, with Cervical Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.

NCT04452526 reports a single indexed study location in Kentucky, Ohio, Virginia.

Frequently Asked Questions

What is clinical trial NCT04452526 about?

NCT04452526 is a clinical study titled "I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination". This trial studies how well a multi-level health system-based intervention works in improving human papillomavirus (HPV) vaccine initiation and completion among children in health systems in four Appalachian states. Utilizing educational and promotional materials and electronic health record reminde...

What is the current status of trial NCT04452526?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 372 participants. The study started on 2020-10-21. Estimated completion is 2025-09.

What conditions does trial NCT04452526 study?

This clinical trial studies the following conditions: Cervical Carcinoma, Human Papillomavirus-Related Malignant Neoplasm.

What interventions are being tested in trial NCT04452526?

The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Educational Intervention (OTHER), Reminder (OTHER).

Who is sponsoring clinical trial NCT04452526?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04452526 being conducted?

This trial has 4 study locations across Kentucky, Ohio, Virginia, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cervical Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04452526's enrollment target sits among peer trials

372 8th of 25 higher than 18 of 25 other Cervical Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cervical Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04801589 · 372 participants · Phase 3

    Goal-Directed Sedation in Mechanically Ventilated Infants and Children

  • NCT04879329 · 372 participants · Phase 2

    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • NCT05318105 · 372 participants · NA

    Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

  • NCT06797635 · 372 participants · Phase 2

    Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04452526, the US trial registry maintained by the National Library of Medicine. NCT04452526 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.